Twinrix Paediatric (hepatitis A (inactivated) and hepatitis B (rDNA) (HAB) vaccine (adsorbed))

Region: 🇪🇺 EU
Active substance: hepatitis A (inactivated) and hepatitis B (rDNA) (HAB) vaccine (adsorbed)
Company: GlaxoSmithKline Biologicals S.A.
Status: Authorised
Therapeutic area: Immunization; Hepatitis B; Hepatitis A
EU approval: Mon 10 Feb 1997
Application: EMEA/H/C/000129
ATC: J07BC20
Official record: www.ema.europa.eu

Indication

Twinrix Paediatric is indicated for use in non-immune infants, children and adolescents from one year up to and including 15 years who are at risk of both hepatitis-A and hepatitis-B infection.

Regulatory milestones

No milestones recorded in the last year.

Same substance in other markets

🇪🇺 Twinrix Adult Authorised · GlaxoSmithKline Biologicals S.A.
🇪🇺 Ambirix Authorised · GlaxoSmithKline Biologicals S.A.

Follow Twinrix Paediatric

Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.

Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.